Redeye leaves a comment on Xspray following the announcement that its HyNap-Dasa 505(b)(2) reached bioequivalence compared to its reference ...
Q3 was slightly mixed, with a strong top line driven by still-high student/child intake (+15.
Organic growth has likely been healthy and we forecast 8.
Lägre försäljning i USA sänkte lönsamheten i Q2 Probis omsättning i Q2 2021 minskade 3% valutajusterat och 12% nominellt till 158 mkr (180).
Redeye ser med spänning fram emot det kommande året då Arise kommer ta de första stegen på sin nya t...
Redeye raises its Base case for Vertiseit following its Q2 report, despite a mixed outcome.
Mangold inleder bevakning av Brilliant Future med rekommendationen Köp och riktkursen 20,50 kronor på 12 månaders sikt.
Q2 sales of SEK 154m, up 24.8% y-o-y (~2% organic) Invisio reported Q1’21 net sales of SEK 154m, +1.
VEF’s 30%+ NAV CAGR track record and improved ESG assessment have become increasingly credited by th...
Q2 details Q2'21 report: Net sales SEK 160m (-2% vs ABGSC 163m and -2% vs cons 163m), EBITDA SEK 47m (5% vs ABGSC 45m and 6% vs cons 45m), A...
Slight sales miss, but profitability in line Eltel delivered weaker sales than expected at EUR 210m ...
Redeye sees an overall solid Q2 report, with robust ARR growth and a pickup in new sales.
Urstarkt kvartal Rapporten för Q2 2021 slog våra och marknadens förväntningar med råge.
Redeye is still hopeful about Bong’s recovery and prospects for sustainable profitability, mainly dr...
Redeye raises its Base case and forecasts following a solid Q2 report, showing significant margin im...
We have previously thought that the Tier-1 card manufacturers would primarily go with their own solutions for biometric cards and that Zwipe...
The 2.1% operative EBITA margin met our estimate Q2 revenue declined by 14% y/y to EUR 210m, vs the ...
Förvärvet av Riaktr stärker i synnerhet SDS:s Business Intelligence-erbjudande och ger därtill tillg...
Redeye argues that the orphan drug designation is another progress and milestone for the company.
Q2’21e preview Swedencare will report its Q2’21 results on Thursday, 29 July.
Eltel’s Q2 produced a sixth consecutive annual improvement in operative EBITA and the result was clo...
Redeye states that Q2 was strong, regarding both revenue and new customer launches.
Redeye maintains its positive outlook despite quarterly sales being somewhat below expectations.
Redeye believes the update from the ILIAD trial confirms the strong safety profile of ilixadencel, n...
On 14 July 2021, the EU adopted a series of legislative proposals with the target to achieve climate neutrality by 2050.
Redeye raises its forecast and Base case following a solid Q2 report beating our forecasts.
We were impressed by Consti’s solid operative progress ahead of a more challenging H2.
Signed combination agreement to create “Fellow Bank” Fellow Finance and Evli Bank signed a combination agreement, by which Evli Bank will de...
Demand is improving somewhat faster than we expected The EUR 35.
Q2 better than expected on adj. basis Consti reported overall slightly better than expected Q2 resul...
